CRF mediates the anxiogenic and anti-rewarding, but not the anorectic effects of PACAP

Neuropsychopharmacology

Volumn 38, Issue 11, 2013, Pages 2160-2169

  Dore, Riccardo ^a   Iemolo, Attilio ^a   Smith, Karen L ^a   Wang, Xiaofan ^a   Cottone, Pietro ^a   Sabino, Valentina ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Amygdala; Anorexia OR anorexic; Anxiety OR anxiolytic; Corticotropin releasing factor OR CRH; Intracranial self stimulation OR ICSS; Pituitary adenylate cyclase activating peptide

Indexed keywords

CORTICOSTERONE; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE;

ANIMAL EXPERIMENT; ANOREXIA; ANXIETY; ARTICLE; CENTRAL NUCLEUS (AMYGDALA); CORTICOSTERONE BLOOD LEVEL; FEAR; FOOD INTAKE; HYPOTHALAMIC PARAVENTRICULAR NUCLEUS; MALE; MAZE TEST; NONHUMAN; PRIORITY JOURNAL; RAT; REWARD; SELF STIMULATION; STRESS; WEIGHT GAIN; WEIGHT REDUCTION;

AMYGDALA; ANIMALS; ANXIETY; BODY WEIGHT; CORTICOSTERONE; CORTICOTROPIN-RELEASING HORMONE; EATING; INFUSIONS, INTRAVENTRICULAR; MALE; MAZE LEARNING; PARAVENTRICULAR HYPOTHALAMIC NUCLEUS; PEPTIDES; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; RATS; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; REWARD; SELF STIMULATION;

EID: 84883304089     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2013.113     Document Type: Article

References (65)

1. Agarwal A, Halvorson LM, Legradi G (2005). Pituitary adenylate cyclase-activating polypeptide (PACAP) mimics neuroendocrine and behavioral manifestations of stress: Evidence for PKAmediated expression of the corticotropin-releasing hormone (CRH) gene. Brain Res Mol Brain Res 138: 45-57.
2. Britton DR, Koob GF, Rivier J, Vale W (1982). Intraventricular corticotropin-releasing factor enhances behavioral effects of novelty. Life Sci 31: 363-367.
3. Britton DR, Varela M, Garcia A, Rosenthal M (1986a). Dexamethasone suppresses pituitary-adrenal but not behavioral effects of centrally administered CRF. Life Sci 38: 211-216.
4. Britton KT, Lee G, Dana R, Risch SC, Koob GF (1986b). Activating and 'anxiogenic' effects of corticotropin releasing factor are not inhibited by blockade of the pituitary-adrenal system with dexamethasone. Life Sci 39: 1281-1286.
5. Carlezon WA Jr., Chartoff EH (2007). Intracranial self-stimulation (ICSS) in rodents to study the neurobiology of motivation. Nat Protoc 2: 2987-2995.
6. Chance WT, Thompson H, Thomas I, Fischer JE (1995). Anorectic and neurochemical effects of pituitary adenylate cyclase activating polypeptide in rats. Peptides 16: 1511-1516.
7. Cottone P, Sabino V, Roberto M, Bajo M, Pockros L, Frihauf JB et al (2009). CRF system recruitment mediates dark side of compulsive eating. Proc Natl Acad Sci USA 106: 20016-20020.
8. Cottone P, Wang X, Park JW, Valenza M, Blasio A, Kwak J et al (2012). Antagonism of sigma-1 receptors blocks compulsive-like eating. Neuropsychopharmacology 37: 2593-2604.
9. Cruz AP, Frei F, Graeff FG (1994). Ethopharmacological analysis of rat behavior on the elevated plus-maze. Pharmacol Biochem Behav 49: 171-176.
10. Davis M (1992). The role of the amygdala in fear and anxiety. Annu Rev Neurosci 15: 353-375.
11. Dunn AJ, Berridge CW (1990). Physiological and behavioral responses to corticotropin-releasing factor administration: is CRF a mediator of anxiety or stress responses? Brain Res Brain Res Rev 15: 71-100.
12. Fekete EM, Zhao Y, Szucs A, Sabino V, Cottone P, Rivier J et al (2011). Systemic urocortin 2, but not urocortin 1 or stressin 1-A, suppresses feeding via CRF2 receptors without malaise and stress. Br J Pharmacol 164: 1959-1975.
13. Fernandes C, File SE (1996). The influence of open arm ledges and maze experience in the elevated plus-maze. Pharmacol Biochem Behav 54: 31-40.
14. File SE, Johnston AL, Baldwin HA (1988). Anxiolytic and anxiogenic drugs: changes in behaviour and endocrine responses. Stress Med 4: 221-230.
15. Funk D, Li Z, Le AD (2006). Effects of environmental and pharmacological stressors on c-fos and corticotropin-releasing factor mRNA in rat brain: Relationship to the reinstatement of alcohol seeking. Neuroscience 138: 235-243.
16. Gottschall PE, Tatsuno I, Miyata A, Arimura A (1990). Characterization and distribution of binding sites for the hypothalamic peptide, pituitary adenylate cyclase-activating polypeptide. Endocrinology 127: 272-277.
17. Grinevich V, Fournier A, Pelletier G (1997). Effects of pituitary adenylate cyclase-activating polypeptide (PACAP) on corticotropin-releasing hormone (CRH) gene expression in the rat hypothalamic paraventricular nucleus. Brain Res 773: 190- 196.
18. Hammack SE, Cheung J, Rhodes KM, Schutz KC, Falls WA, Braas KM et al (2009). Chronic stress increases pituitary adenylate cyclase-activating peptide (PACAP) and brain-derived neurotrophic factor (BDNF) mRNA expression in the bed nucleus of the stria terminalis (BNST): roles for PACAP in anxiety-like behavior. Psychoneuroendocrinology 34: 833-843.
19. Hannibal J (2002). Pituitary adenylate cyclase-activating peptide in the rat central nervous system: an immunohistochemical and in situ hybridization study. J Comp Neurol 453: 389-417.
20. Hannibal J, Jessop DS, Fahrenkrug J, Harbuz MS, Larsen PJ (1999). PACAP gene expression in neurons of the rat hypothalamopituitary- adrenocortical axis is induced by endotoxin and interleukin-1beta. Neuroendocrinology 70: 73-82.
21. Hannibal J, Mikkelsen JD, Fahrenkrug J, Larsen PJ (1995). Pituitary adenylate cyclase-activating peptide gene expression in corticotropin- releasing factor-containing parvicellular neurons of the rat hypothalamic paraventricular nucleus is induced by colchicine, but not by adrenalectomy, acute osmotic, ether, or restraint stress. Endocrinology 136: 4116-4124.
22. Harmar AJ, Arimura A, Gozes I, Journot L, Laburthe M, Pisegna JR et al (1998). International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol Rev 50: 265-270.
23. Hashimoto H, Shintani N, Tanaka K, Mori W, Hirose M, Matsuda T et al (2001). Altered psychomotor behaviors in mice lacking pituitary adenylate cyclase-activating polypeptide (PACAP). Proc Natl Acad Sci USA 98: 13355-13360.
24. Heinrichs SC, Menzaghi F, Schulteis G, Koob GF, Stinus L (1995). Suppression of corticotropin-releasing factor in the amygdala attenuates aversive consequences of morphine withdrawal. Behav Pharmacol 6: 74-80.
25. Heinrichs SC, Pich EM, Miczek KA, Britton KT, Koob GF (1992). Corticotropin-releasing factor antagonist reduces emotionality in socially defeated rats via direct neurotropic action. Brain Res 581: 190-197.
26. Iemolo A, Valenza M, Tozier L, Knapp CM, Kornetsky C, Steardo L et al (2012). Withdrawal from chronic, intermittent access to a highly palatable food induces depressive-like behavior in compulsive eating rats. Behav Pharmacol 23: 593-602.
27. Kageyama K, Hanada K, Iwasaki Y, Sakihara S, Nigawara T, Kasckow J et al (2007). Pituitary adenylate cyclase-activating polypeptide stimulates corticotropin-releasing factor, vasopressin and interleukin-6 gene transcription in hypothalamic 4B cells. J Endocrinol 195: 199-211.
28. Kalin NH, Takahashi LK, Chen FL(1994). Restraint stress increases corticotropin-releasing hormone mRNA content in the amygdala and paraventricular nucleus. Brain Res 656: 182-186.
29. Kenny PJ, Markou A (2005). Conditioned nicotine withdrawal profoundly decreases the activity of brain reward systems J Neurosci 25: 6208-6212.
30. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE (2005). Prevalence, severity, and comorbidity of 12-month DSMIV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62: 617-627.
31. Koob GF, Heinrichs SC (1999). A role for corticotropin releasing factor and urocortin in behavioral responses to stressors. Brain Res 848: 141-152.
32. Koob GF, Zorrilla EP (2012). Update on corticotropin-releasing factor pharmacotherapy for psychiatric disorders: a revisionist view. Neuropsychopharmacology 37: 308-309.
33. Kornetsky C, Esposito RU, McLean S, Jacobson JO (1979). Intracranial self-stimulation thresholds: a model for the hedonic effects of drugs of abuse. Arch Gen Psychiatry 36: 289-292.
34. Legradi G, Das M, Giunta B, Hirani K, Mitchell EA, Diamond DM (2007). Microinfusion of pituitary adenylate cyclase-activating polypeptide into the central nucleus of amygdala of the rat produces a shift from an active to passive mode of coping in the shock-probe fear/defensive burying test. Neural Plast 2007: 79102.
35. Lehmann ML, Mustafa T, Eiden AM, Herkenham M, Eiden LE (2012). PACAP-deficient mice show attenuated corticosterone secretion and fail to develop depressive behavior during chronic social defeat stress. Psychoneuroendocrinology 38: 702-715.
36. Li S, Grinevich V, Fournier A, Pelletier G (1996). Effects of pituitary adenylate cyclase-activating polypeptide (PACAP) on gonadotropin-releasing hormone and somatostatin gene expression in the rat brain. Brain Res Mol Brain Res 41: 157-162.
37. Macey DJ, Koob GF, Markou A (2000). CRF and urocortin decreased brain stimulation reward in the rat: reversal by a CRF receptor antagonist. Brain Res 866: 82-91.
38. Makino S, Shibasaki T, Yamauchi N, Nishioka T, Mimoto T, Wakabayashi I et al (1999). Psychological stress increased corticotropin-releasing hormone mRNA and content in the central nucleus of the amygdala but not in the hypothalamic paraventricular nucleus in the rat. Brain Res 850: 136-143.
39. Markou A, Koob GF (1991). Postcocaine anhedonia. An animal model of cocaine withdrawal. Neuropsychopharmacology 4: 17-26.
40. Markou A, Koob GF (1992). Construct validity of a self-stimulation threshold paradigm: effects of reward and performance manipulations. Physiol Behav 51: 111-119.
41. Maruyama K, Miura T, Uchiyama M, Shioda S, Matsuda K (2006). Relationship between anorexigenic action of pituitary adenylate cyclase-activating polypeptide (PACAP) and that of corticotropin- releasing hormone (CRH) in the goldfish, Carassius auratus. Peptides 27: 1820-1826.
42. Matsuda K, Maruyama K, Nakamachi T, Miura T, Uchiyama M, Shioda S (2005). Inhibitory effects of pituitary adenylate cyclaseactivating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) on food intake in the goldfish, Carassius auratus. Peptides 26: 1611-1616.
43. Menzaghi F, Rassnick S, Heinrichs S, Baldwin H, Pich EM, Weiss F et al (1994). The role of corticotropin-releasing factor in the anxiogenic effects of ethanol withdrawal. Ann N Y Acad Sci 739: 176-184.
44. Merlo Pich E, Lorang M, Yeganeh M, Rodriguez de Fonseca F, Raber J, Koob GF et al (1995). Increase of extracellular corticotropin-releasing factor-like immunoreactivity levels in the amygdala of awake rats during restraint stress and ethanol withdrawal as measured by microdialysis. J Neurosci 15: 5439-5447.
45. Miyata A, Arimura A, Dahl RR, Minamino N, Uehara A, Jiang L et al (1989). Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem Biophys Res Commun 164: 567-574.
46. Morley JE, Levine AS (1982). Corticotrophin releasing factor, grooming and ingestive behavior. Life Sci 31: 1459-1464.
47. Mounien L, Do Rego JC, Bizet P, Boutelet I, Gourcerol G, Fournier A et al (2009). Pituitary adenylate cyclase-activating polypeptide inhibits food intake in mice through activation of the hypothalamic melanocortin system. Neuropsychopharmacology 34: 424-435.
48. Norrholm SD, Das M, Legradi G (2005). Behavioral effects of local microinfusion of pituitary adenylate cyclase activating polypeptide (PACAP) into the paraventricular nucleus of the hypothalamus (PVN). Regul Pept 128: 33-41.
49. Otto C, Martin M, Wolfer DP, Lipp HP, Maldonado R, Schutz G (2001). Altered emotional behavior in PACAP-type-I-receptordeficient mice. Brain Res Mol Brain Res 92: 78-84.
50. Paxinos G, Watson C (2007). The Rat Brain. 6th edn. Academic Press: Orlando, FL.
51. Piggins HD, Stamp JA, Burns J, Rusak B, Semba K (1996). Distribution of pituitary adenylate cyclase activating polypeptide (PACAP) immunoreactivity in the hypothalamus and extended amygdala of the rat. J Comp Neurol 376: 278-294.
52. Rassnick S, Heinrichs SC, Britton KT, Koob GF (1993). Microinjection of a corticotropin-releasing factor antagonist into the central nucleus of the amygdala reverses anxiogenic-like effects of ethanol withdrawal. Brain Res 605: 25-32.
53. Resch JM, Boisvert JP, Hourigan AE, Mueller CR, Yi SS, Choi S (2011). Stimulation of the hypothalamic ventromedial nuclei by pituitary adenylate cyclase-activating polypeptide induces hypophagia and thermogenesis. Am J Physiol Regul Integr Comp Physiol 301: R1625-R1634.
54. Ressler KJ, Mercer KB, Bradley B, Jovanovic T, Mahan A, Kerley K et al (2011). Post-traumatic stress disorder is associated with PACAP and the PAC1 receptor. Nature 470: 492-497.
55. Rodriguez de Fonseca F, Rubio P, Menzaghi F, Merlo-Pich E, Rivier J, Koob GF et al (1996). Corticotropin-releasing factor (CRF) antagonist [D-Phe12,Nle21,38,C alpha MeLeu37]CRF attenuates the acute actions of the highly potent cannabinoid receptor agonist HU-210 on defensive-withdrawal behavior in rats. J Pharmacol Exp Ther 276: 56-64.
56. Sabino V, Cottone P, Blasio A, Iyer MR, Steardo L, Rice KC et al (2011). Activation of sigma-receptors induces binge-like drinking in Sardinian alcohol-preferring rats. Neuropsychopharmacology 36: 1207-1218.
57. Sabino V, Cottone P, Zhao Y, Iyer MR, Steardo L Jr., Steardo L et al (2009). The sigma-receptor antagonist BD-1063 decreases ethanol intake and reinforcement in animal models of excessive drinking. Neuropsychopharmacology 34: 1482-1493.
58. Schulteis G, Markou A, Cole M, Koob GF (1995). Decreased brain reward produced by ethanol withdrawal. Proc Natl Acad Sci USA 92: 5880-5884.
59. Sherwood NM, Krueckl SL, McRory JE (2000). The origin and function of the pituitary adenylate cyclase-activating polypeptide (PACAP)/glucagon superfamily. Endocr Rev 21: 619-670.
60. Stroth N, Eiden LE (2010). Stress hormone synthesis in mouse hypothalamus and adrenal gland triggered by restraint is dependent on pituitary adenylate cyclase-activating polypeptide signaling. Neuroscience 165: 1025-1030.
61. Tachibana T, Saito ES, Takahashi H, Saito S, Tomonaga S, Boswell T et al (2004). Anorexigenic effects of pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal peptide in the chick brain are mediated by corticotrophin-releasing factor. Regul Pept 120: 99-105.
62. Tachibana T, Saito S, Tomonaga S, Takagi T, Saito ES, Boswell T et al (2003). Intracerebroventricular injection of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibits feeding in chicks. Neurosci Lett 339: 203-206.
63. Zacharko RM, Anisman H (1991). Stressor-induced anhedonia in the mesocorticolimbic system. Neurosci Biobehav Rev 15: 391- 405.
64. Zorrilla EP, Schulteis G, Ormsby A, Klaassen A, Ling N, McCarthy JR et al (2002). Urocortin shares the memory modulating effects of corticotropin- releasing factor (CRF): mediation by CRF1 receptors. Brain Res 952: 200-210.
65. Zorrilla EP, Valdez GR, Weiss F (2001). Changes in levels of regional CRF-like-immunoreactivity and plasma corticosterone during protracted drug withdrawal in dependent rats. Psychopharmacology (Berl) 158: 374-381.